Ventyx Biosciences Announces Departure Of Martin Auster As Chief Financial Officer, Effective August 30, 2024; The Company Has Initiated A Search For A CFO

Author: Benzinga Newsdesk | August 30, 2024 08:06am

Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.

Posted In: VTYX